| AMGN:Amgen Inc | | Charting | News | Options | |||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
1.17% $3.49
 Markets |
 Portfolio |
| |
| |
|
| |
|
|
|
|||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||
|
| Latest Story |
|
| AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER |
|
| PR Newswire |
|
At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis. |
| Full Story → |
|
| Headline News |
|
| RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS |
| 2:31p ET June 23 '25 PR Newswire |
|
|
| AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE |
| 4:01p ET May 16 '25 PR Newswire |
|
|
| AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE |
| 4:01p ET May 9 '25 PR Newswire |
|
| More News → |
| ||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| July 18 '25. Markets Closed. | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Previous data from yesterday, July 17 '25. | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Historical Price Performance | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
Market data provided by 
News provided by   |
1.77%
